RichardM.GreenMD

PubMed

• 11 citations
  Cancer stem cell assay-guided chemotherapy improves survival of patients with recurrent glioblastoma in a randomized trial.
  Tulika Ranjan, Soma Sengupta, Michael J Glantz, Richard M Green, Alexander Yu, Dawit Aregawi, Rekha Chaudhary, Ricky Chen, Mario Zuccarello, Christine Lu-Emerson, Hugh...> ;Cell Reports. Medicine. 2023 May 16
• 2 citations
  Whole Exome Sequencing Identifies PHF14 Mutations in Neurocytoma and Predicts Responsivity to the PDGFR Inhibitor Sunitinib.
  Dongyun Zhang, William Yong, Masoud Movassaghi, Fausto J Rodriguez, Issac Yang, Paul McKeever, Jiang Qian, Jian Yi Li, Qinwen Mao, Kathy L Newell, Richard M Green, Cyn...> ;Biomedicines. 2022 Nov 8
• 6 citations
  Prognostic value of-methylguanine-DNA methyltransferase methylation in isocitrate dehydrogenase mutant gliomas.
  Keng Lam, Blaine S C Eldred, Bryan Kevan, Sean Pianka, Brittany A Eldred, Serendipity Zapanta Rinonos, William H Yong, Linda M Liau, Phioanh L Nghiemphu, Timothy F Clo...> ;Neuro-Oncology Advances. 2022 Mar 1
• 5 citations
  Patterns of long-term survivorship following bevacizumab treatment for recurrent glioma: a case series.
  Liang Yen Liu, Matthew Ji, Nhung T Nguyen, Frances Chow, Donna Molaie, Sean T Pianka, Richard M. Green, Linda M. Liau, Benjamin M. Ellingson, Phioanh L. Nghiemphu, Tim...> ;CNS Oncology. 2019 Jun 1
• 4 citations
  Somatostatin Receptor Ligand Therapy-A Potential Therapy for Neurocytoma.
  Dongyun Zhang, Sarah S R Kim, Daniel F. Kelly, Sylvia L. Asa, Masoud Movassaghi, Sergey Mareninov, William H. Yong, Timothy F. Cloughesy, Fausto J. Rodriguez, Paul E. ...> ;The Journal of Clinical Endocrinology and Metabolism. 2019 Jun 1
• 3 citations
  Correlation of commercially available quantitative MGMT (O-6-methylguanine-DNA methyltransferase) promoter methylation scores and GBM patient survival.
  Laura Dovek, Nhung T Nguyen, Byram Ozer, Ning Li, Robert Elashoff, Richard M. Green, Linda M. Liau, P Leia Nghiemphu, Timothy F. Cloughesy, Albert Lai> ;Neuro-Oncology Practice. 2019 May 7
• 3 citations
  Bevacizumab at first recurrence after standard radio-chemotherapy is associated with improved overall survival in glioblastoma patients with large tumor burden.
  Huy Tram N. Nguyen, Nhung T Nguyen, Liang Yen Liu, Laura Dovek, Daniel Lenchner, Robert Harris, Byram Ozer, Arliene Ravelo, Nicolas Sommer, Myung-Shin Sim, Robert Elas...> ;Neuro-Oncology Practice. 2019 Mar 29
• 9 citations
  Correction: First results on survival from a large Phase 3 clinical trial of an autologous dendritic cell vaccine in newly diagnosed glioblastoma [J Transl Med., 16, (...
  Linda M. Liau, Keyoumars Ashkan, David Tran, Jian Campian, John E. Trusheim, Charles S. Cobbs, Jason Heth, Michael Salacz, Sarah A. Taylor, Stacy D. D’Andre, Fabio M. ...> ;Journal of Translational Medicine. 2018 Jun 29
• 39 citations
  Phase 2 Study of Bortezomib Combined With Temozolomide and Regional Radiation Therapy for Upfront Treatment of Patients With Newly Diagnosed Glioblastoma Multiforme: S...
  Xiao-Tang Kong, Nhung T Nguyen, Yoon Jeong Choi, Guicheng Zhang, Huytram N. Nguyen, Emese Filka, Stacey Green, William H. Yong, Linda M. Liau, Richard M. Green, Tania ...> ;International Journal of Radiation Oncology, Biology, Physics. 2018 Apr 1
• 20 citations
  Report of safety of pulse dosing of lapatinib with temozolomide and radiation therapy for newly-diagnosed glioblastoma in a pilot phase II study.
  Andrew Yu, Nadia Faiq, Stacey Green, Albert Lai, Richard M. Green, Jethro Hu, Timothy F. Cloughesy, Ingo K. Mellinghoff, P Leia Nghiemphu> ;Journal of Neuro-Oncology. 2017 Jul 1
• 2 citations
  Banning Therapy to Change Sexual Orientation or Gender Identity in Patients Under 18.
  Richard Green> ;The Journal of the American Academy of Psychiatry and the Law. 2017 Mar 1
• 73 citations
  Human TERT promoter mutation enables survival advantage from MGMT promoter methylation in IDH1 wild-type primary glioblastoma treated by standard chemoradiotherapy
  Huytram N. Nguyen, Amy Lie, Tie Li, Reshmi Chowdhury, Fei Liu, Byram Ozer, Bowen Wei, Richard M. Green, Benjamin M. Ellingson, He-Jing Wang, Robert Elashoff, Linda M. ...> ;Neuro-Oncology. 2016 Aug 29
• Deferred use of bevacizumab for recurrent glioblastoma is not associated with diminished efficacy.
  Piccioni DE, Selfridge J, Mody RR, Chowdhury R, Li S, Lalezari S, Wawrzynski J, Quan J, Zurayk M, Chou AP, Sanchez DE, Liau LM, Ellingson BM, Pope WB, Nghiemphu PL, Gr...> ;Neuro-oncology. 2014-06-01
• 85 citations
  Combined analysis of O6-methylguanine-DNA methyltransferase protein expression and promoter methylation provides optimized prognostication of glioblastoma outcome
  Shadi Lalezari, Arthur P. Chou, Anh Tran, Orestes E. Solis, Negar Khanlou, Weidong Chen, Sichen Li, Jose Carrillo, Reshmi Chowdhury, Julia Selfridge, Desiree Sanchez, ...> ;Neuro-Oncology. 2013 Mar 1
• 10 citations
  A dose escalation trial for the combination of erlotinib and sirolimus for recurrent malignant gliomas.
  Phioanh L. Nghiemphu, Albert Lai, Richard M. Green, David A. Reardon, Timothy F. Cloughesy> ;Journal of Neuro-Oncology. 2012 Aug 24
• 38 citations
  Initial treatment patterns over time for anaplastic oligodendroglial tumors.
  , , , , , , , , , , , , , , , , , , , , , , , , , > ;Neuro-Oncology. 2012 Jun 1
• 58 citations
  Rosette-forming glioneuronal tumor: a pineal region case with IDH1 and IDH2 mutation analyses and literature review of 43 cases
  Orestes E. Solis, Rupal I. Mehta, Albert Lai, Rashi I Mehta, Lama O. Farchoukh, Richard M. Green, Jerry C. Cheng, Sathima Natarajan, Harry V. Vinters, Timothy F. Cloug...> ;Journal of Neuro-Oncology. 2011 May 1
• 361 citations
  Phase II Study of Bevacizumab Plus Temozolomide During and After Radiation Therapy for Patients With Newly Diagnosed Glioblastoma Multiforme
  Albert Lai, Anh Tran, Phioanh L. Nghiemphu, Whitney B. Pope, Orestes E. Solis, Michael T. Selch, Emese Filka, William H. Yong, Paul S. Mischel, Linda M. Liau, Surasak ...> ;Journal of Clinical Oncology. 2011 Jan 10
• 46 citations
  Bevacizumab for recurrent ependymoma.
  Richard M. Green, Timothy F. Cloughesy, Roger Stupp, Lisa M. DeAngelis, Emily Woyshner, Douglas E. Ney, Andrew B. Lassman> ;Neurology. 2009 Nov 17
• Phase II trial of bevacizumab in combination with temozolomide and regional radiation therapy for up-front treatment of patients with newly diagnosed glioblastoma mult...
  Lai A, Nghiemphu P, Green R, Spier L, Peak S, Phuphanich S, Fehrenbacher L, Kolevska T, Polikoff J, Cloughesy T> ;J. Clin. Oncol.. 2009-05-20
• 193 citations
  Bevacizumab and chemotherapy for recurrent glioblastoma A single-institution experience
  Phioanh L. Nghiemphu, W. Liu, Yohan Lee, Tin Aung Than, C. Graham, Albert Lai, Richard M. Green, Whitney B. Pope, Linda M. Liau, Paul S. Mischel, Stan F. Nelson, Rober...> ;Neurology. 2009 Apr 7
• 68 citations
  Safety of anticoagulation use and bevacizumab in patients with glioma
  Phioanh L. Nghiemphu, Richard M. Green, Whitney B. Pope, Albert Lai, Timothy F. Cloughesy> ;Neuro-Oncology. 2008 Jun 1
• A retrospective single institutional analysis of bevacizumab and chemotherapy versus non-bevacizumab treatments for recurrent glioblastoma.
  Nghiemphu P, Graham C, Liu W, Than T, Lai A, Green R, Elashoff RM, Cloughesy TF> ;J. Clin. Oncol.. 2008-05-20
• 449 citations
  Antitumor Activity of Rapamycin in a Phase I Trial for Patients with Recurrent PTEN-Deficient Glioblastoma
  Timothy F. Cloughesy, Koji Yoshimoto, Phioanh L. Nghiemphu, Kevin M. Brown, Julie Dang, Shaojun Zhu, Teli Hsueh, Yinan Chen, Wei-wei Wang, David Youngkin, Linda M. Lia...> ;Plos Medicine. 2008 Jan 22
• 4 citations
  CIDP masquerading as uremic polyneuropathy.
  Richard M. Green> ;Neurology. 1992 Jun 1
• Join now to see all